Medical Cannabis Advocacy in South Asia During the 1970s

Historical Context: Cannabis in South Asian Medicine

Cannabis (primarily Cannabis sativa) held a documented place in South Asian medical traditions for centuries. Ayurvedic and Unani medical texts referenced cannabis preparations—known as bhang, ganja, and charas in regional variants—for treating pain, digestive disorders, and insomnia. ^[1] This historical precedent shaped 1970s medical discussions; advocates could point to centuries of recorded use rather than proposing cannabis as a novel therapeutic. Strong evidence

Following Indian independence (1947) and the partition of Pakistan (1947), South Asian governments inherited colonial drug policies that largely criminalized cannabis production and sale under the Dangerous Drugs Act and similar statutes. ^[2] However, traditional medical practitioners continued to use cannabis preparations, and the legal and cultural landscape differed markedly from Western prohibitionist models—particularly in India, where cannabis retained cultural and religious significance and was not universally criminalized for traditional use. Strong evidence

By the 1970s, South Asian nations were constructing independent drug policy frameworks while navigating international pressure from the UN Commission on Narcotic Drugs and the 1961 Single Convention on Narcotic Drugs. This created a policy window in which some medical researchers and traditional practitioners advocated for cannabis reclassification or exemption on therapeutic grounds. Weak / limited

Indian Medical Advocacy and Research (1970–1979)

India became the focal point for South Asian cannabis medical advocacy during the 1970s. The Indian medical and scientific community engaged in published and institutional debate over cannabis therapeutics, though the volume and rigor of clinical research was limited compared to later decades. Weak / limited

In 1975, the Indian government convened discussions on cannabis policy within the Ministry of Health and Family Planning, prompted in part by traditional medical practitioners' requests for legal recognition of cannabis use in Ayurvedic and Unani medicine. ^[3] These discussions included research institutions such as the All India Institute of Medical Sciences (AIIMS) and the Central Council for Research in Ayurveda and Siddha (CCRAS). However, most advocacy remained in policy and traditional medicine circles rather than in controlled clinical trials. Weak / limited

Key figures in Indian medical advocacy included practitioners and researchers affiliated with CCRAS and Ayurvedic colleges, though detailed records of individual advocates are sparse in English-language historical sources. The Indian Journal of Medical Research and other domestic medical journals published occasional articles discussing cannabis pharmacology and historical use, but these did not constitute systematic clinical investigation. Weak / limited

India's position differed from Western medical establishments: cannabis was not legally prohibited for all uses (licensed shops still sold cannabis products under medical regulation in some states), and traditional medicine retention created political constituency for continued cannabis access. Strong evidence This structural difference meant Indian advocacy was not fighting criminalization entirely, but rather negotiating the terms of legalization within a mixed traditional-modern medical system. Weak / limited

Pakistan and Bangladesh: Limited Documented Advocacy

Pakistan and Bangladesh—newly independent or partitioned during this era—left far less documented record of 1970s cannabis medical advocacy. No data

Pakistan implemented strict cannabis prohibition under the Opium Act and subsequent drug legislation, influenced by both colonial inheritance and Islamic jurisprudence that framed cannabis use as problematic. ^[2] No major medical advocacy for cannabis therapeutics emerged in published Pakistani medical literature during the 1970s, though traditional use in Unani medicine persisted in practice. No data

Bangladesh, independent only from 1971, prioritized health system construction and faced limited capacity for domestic drug policy debate. Cannabis remained criminalized under inherited colonial legislation, and no significant medical advocacy for cannabis reclassification was documented in English-language sources. No data

This geographical asymmetry—with India dominating documented advocacy—reflects both India's larger medical research infrastructure and its different legal and cultural relationship to cannabis. Pakistani and Bangladeshi medical professionals may have privately held views on cannabis therapeutics, but such perspectives did not translate into documented institutional advocacy during this period. Weak / limited

International Pressure and the WHO Single Convention

The 1961 UN Single Convention on Narcotic Drugs and its 1972 Protocol classified cannabis as a Schedule IV controlled substance—the most restrictive category—creating international pressure on all signatory nations to criminalize cannabis production and trade. India, Pakistan, and Bangladesh were all signatories, binding them to increasingly strict prohibition frameworks. Strong evidence

During the 1970s, WHO discussions about cannabis scheduling occurred in Geneva, with South Asian nations represented in these debates. India's representatives advocated, to varying degrees, for recognition of cannabis's therapeutic potential and cultural/traditional medicine role, but these positions were minority viewpoints within a globally prohibitionist consensus. Weak / limited The international momentum toward stricter scheduling ultimately prevailed over arguments for therapeutic exemption. Strong evidence

This external pressure constrained South Asian advocates. Even if domestic medical communities recognized cannabis's therapeutic utility, international treaty obligations limited policy autonomy. India's ability to maintain licensed cannabis sale for traditional medicine was tolerated as a legacy exception, but new therapeutic research or expansion of cannabis access faced international scrutiny. Weak / limited

Myth of 1970s 'Proof' of Cannabis Efficacy

A persistent historical narrative claims that India (and by extension, South Asia) 'proved' cannabis efficacy for various conditions during the 1970s, and that Western prohibition ignored this evidence. Anecdote This claim requires scrutiny.

The actual clinical evidence base from 1970s South Asian research was weak. Weak / limited While traditional medicine textbooks documented cannabis use across centuries, and while advocacy discussions occurred in Indian health ministries, systematic controlled trials demonstrating efficacy were not published from South Asian institutions during the 1970s. Weak / limited Most 1970s discussion cited historical precedent and mechanism-of-action theories rather than new clinical data. Weak / limited

The confusion likely arises from conflating three distinct phenomena: (1) documented historical use in traditional medicine [strong evidence], (2) continued advocacy for therapeutic recognition [weak-to-anecdotal evidence for specific efficacy claims], and (3) perceived Western dismissal of non-Western medical systems [strong evidence that this dismissal occurred, but not evidence that the medical claims themselves were robust]. Strong evidence

Modern systematic reviews have found that high-quality clinical evidence for cannabis efficacy was scant globally through the 1970s, including in South Asia. ^[4] The mythology of 1970s South Asian 'proof' reflects a retrospective desire to claim historical vindication rather than an accurate characterization of the evidence record at the time. Weak / limited

Legacy and Historiographical Gaps

The 1970s South Asian cannabis advocacy movement left limited institutional or archival record, particularly in English-language sources accessible to global researchers. Government ministries in India, Pakistan, and Bangladesh held relevant files, but many remain inaccessible or undigitized. Traditional medicine institutions in India maintain some institutional memory, but formal historical documentation is sparse. Weak / limited

This fragmentation has allowed mythology to flourish. Without robust primary-source documentation, claims about 1970s South Asian cannabis research circulate in cannabis advocacy communities without systematic verification. Anecdote Genuine historical facts—that India maintained legal cannabis access for traditional medicine, that medical institutions discussed therapeutic potential, that international prohibition was externally imposed—become conflated with unsupported claims about clinical efficacy or government-sponsored research programs. Weak / limited

Future historical work would benefit from: (1) excavation of South Asian government archives on 1970s drug policy, (2) compilation of traditional medicine institutional records, (3) analysis of contemporary medical journal articles from India, Pakistan, and Bangladesh, and (4) oral history interviews with surviving practitioners and policy figures. No data This work has not yet been substantially undertaken in English-language scholarship. Weak / limited

What is clear: South Asian nations in the 1970s inhabited a different legal and cultural relationship to cannabis than Western nations, and medical advocacy for therapeutic use occurred within that context. But claims about the strength and scope of that advocacy require documentation rather than assumption. Weak / limited

Sources

How this page was made